Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Is Uncertainty Quantification a Viable Alternative to Learned Deferral?
0
Zitationen
2
Autoren
2025
Jahr
Abstract
Artificial Intelligence (AI) holds the potential to dramatically improve patient care. However, it is not infallible, necessitating human-AI-collaboration to ensure safe implementation. One aspect of AI safety is the models' ability to defer decisions to a human expert when they are likely to misclassify autonomously. Recent research has focused on methods that learn to defer by optimising a surrogate loss function that finds the optimal trade-off between predicting a class label or deferring. However, during clinical translation, models often face challenges such as data shift. Uncertainty quantification methods aim to estimate a model's confidence in its predictions. However, they may also be used as a deferral strategy which does not rely on learning from specific training distribution. We hypothesise that models developed to quantify uncertainty are more robust to out-of-distribution (OOD) input than learned deferral models that have been trained in a supervised fashion. To investigate this hypothesis, we constructed an extensive evaluation study on a large ophthalmology dataset, examining both learned deferral models and established uncertainty quantification methods, assessing their performance in- and out-of-distribution. Specifically, we evaluate their ability to accurately classify glaucoma from fundus images while deferring cases with a high likelihood of error. We find that uncertainty quantification methods may be a promising choice for AI deferral.
Ähnliche Arbeiten
Optical Coherence Tomography
1991 · 13.616 Zit.
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
2016 · 7.288 Zit.
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
2014 · 6.765 Zit.
YOLOv3: An Incremental Improvement
2018 · 5.887 Zit.
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 · 5.826 Zit.